Teresa M Seccia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4138291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
2	Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. Cardiovascular Research, 2022, 118, 988-1003.	3.8	12
3	Modern Management of Hypertensive Emergencies. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 33-40.	2.2	4
4	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	2.7	13
5	Peptidergic G Protein–Coupled Receptor Regulation of Adrenal Function: Bench to Bedside and Back. Endocrine Reviews, 2022, 43, 1038-1050.	20.1	6
6	Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells. International Journal of Molecular Sciences, 2022, 23, 5125.	4.1	11
7	The cardiovascular consequences of hyperaldosteronism. Annales D'Endocrinologie, 2021, 82, 174-178.	1.4	9
8	High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension. Cardiovascular Research, 2021, 117, 1372-1381.	3.8	27
9	Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone. Blood Pressure, 2021, 30, 133-137.	1.5	6
10	Urinary sodium potassium ratio is associated with clinical success after adrenalectomy in patients with unilateral primary aldosteronism. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110226.	2.5	0
11	Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex. Journal of Hypertension, 2021, 39, 1577-1585.	0.5	9
12	HIGH SODIUM INTAKE INDUCES A CATABOLIC STATE VIA GLOMERULAR HYPERFILTRATION AND ENHANCED GLOMERULOTUBULAR BALANCE IN PATIENTS WITH ESSENTIAL HYPERTENSION. Journal of Hypertension, 2021, 39, e78.	0.5	0
13	THE 2020 ITALIAN SOCIETY OF HYPERTENSION (SIIA) PRACTICAL GUIDELINES FOR THE MANAGEMENT OF PRIMARY ALDOSTERONISM. Journal of Hypertension, 2021, 39, e62.	0.5	5
14	ACE2 AND ANGIOTENSIN-(1-7) AND ALDOSTERONE BIOSYNTHESIS IN HUMAN ADRENOCORTICAL TISSUES. Journal of Hypertension, 2021, 39, e60.	0.5	0
15	EFFECTS OF ACE INHIBITORS AND ANGIOTENSIN TYPE-1 RECEPTOR BLOCKERS ON ACE-2 EXPRESSION IN HUMAN ALVEOLAR EPITHELIAL CELLS. Journal of Hypertension, 2021, 39, e414.	0.5	0
16	Management of hypertensive emergencies: a practical approach. Blood Pressure, 2021, 30, 208-219.	1.5	4
17	A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy. Endocrine, 2021, 74, 5-10.	2.3	8
18	Angiotensin peptides in the regulation of adrenal cortical function. Exploration of Medicine, 2021, 2, 294-304.	1.5	2

#	Article	IF	CITATIONS
19	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	3.6	18
20	Letter to the Editor from Rui Zhu et al: "Performance of the Aldosterone-to-Renin Ratio as a Screening Test for Primary Aldosteronism: A Systematic Review and Meta-Analysis― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4292-e4293.	3.6	2
21	Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. Journal of Hypertension, 2020, 38, 332-339.	0.5	48
22	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^–. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
23	Primary aldosteronism in elderly, old, and very old patients. Journal of Human Hypertension, 2020, 34, 807-813.	2.2	4
24	Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 547-560.	2.2	38
25	ROCK (RhoA/Rho Kinase) in Cardiovascular–Renal Pathophysiology: A Review of New Advancements. Journal of Clinical Medicine, 2020, 9, 1328.	2.4	51
26	Disease monitoring of Primary Aldosteronism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101417.	4.7	4
27	High Blood Pressure Is Associated with Tubulointerstitial Damage along with Glomerular Damage in Glomerulonephritis. A large Cohort Study. Journal of Clinical Medicine, 2020, 9, 1656.	2.4	5
28	Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism—the EMIRA Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2060-2067.	3.6	30
29	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
30	Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: a proof-of-concept study. Clinical Science, 2020, 134, 1265-1278.	4.3	7
31	PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3726-3734.	3.6	22
32	The Key Role of Epithelial to Mesenchymal Transition (EMT) in Hypertensive Kidney Disease. International Journal of Molecular Sciences, 2019, 20, 3567.	4.1	23
33	Aldosterone Stimulates Its Biosynthesis Via a Novel GPER-Mediated Mechanism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6316-6324.	3.6	15
34	AT1AA (Angiotensin II Type-1 Receptor Autoantibodies). Hypertension, 2019, 74, 793-799.	2.7	13
35	Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressure. Steroids, 2019, 152, 108486.	1.8	17
36	A sleep apnoea questionnaire predicts organ damage in hypertensive patients. Blood Pressure, 2019, 28, 173-183.	1.5	0

#	Article	IF	CITATIONS
37	Primary Aldosteronism: A Glimpse into the Most Common Endocrine Cause of Arterial Hypertension. , 2019, , .		0
38	Editorial: Endocrine Forms of Hypertension: Clinical and Emerging Molecular Aspects. Frontiers in Endocrinology, 2019, 10, 857.	3.5	0
39	Adrenal Venous Sampling. Endocrinology and Metabolism Clinics of North America, 2019, 48, 843-858.	3.2	19
40	Arterial Hypertension, Aldosterone, and Atrial Fibrillation. Current Hypertension Reports, 2019, 21, 94.	3.5	22
41	Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone–renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design. Journal of Human Hypertension, 2019, 33, 167-171.	2.2	6
42	Abstract 058: High Sodium Intake Induces a Catabolic State via Glomerular Hyperfiltration and Enhanced Glomerulotubular Balance in Essential Hypertension. Hypertension, 2019, 74, .	2.7	0
43	Is exercise becoming a danger for our health? The complex relationship between exercise and atrial fibrillation. European Journal of Preventive Cardiology, 2018, 25, 621-623.	1.8	5
44	The angiotensin type 2 receptor in the human adrenocortical zona glomerulosa and in aldosterone-producing adenoma: low expression and no functional role. Clinical Science, 2018, 132, 627-640.	4.3	17
45	The subtyping of primary aldosteronism by adrenal vein sampling. Journal of Hypertension, 2018, 36, 335-343.	0.5	24
46	Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide. Surgery, 2018, 163, 789-795.	1.9	28
47	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. Journal of Hypertension, 2018, 36, 451-461.	0.5	19
48	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. Journal of Hypertension, 2018, 36, 462-471.	0.5	13
49	The Biology of Normal Zona Glomerulosa And Aldosterone-Producing Adenoma: Pathological Implications. Endocrine Reviews, 2018, 39, 1029-1056.	20.1	40
50	Smoking causes atrial fibrillation? Further evidence on a debated issue. European Journal of Preventive Cardiology, 2018, 25, 1434-1436.	1.8	4
51	Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism. Hypertension, 2017, 69, 545-550.	2.7	59
52	Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. Journal of Hypertension, 2017, 35, 205-212.	0.5	93
53	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, .	3.7	64
54	The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale and Design of a Randomized Study (I-Padua). High Blood Pressure and Cardiovascular Prevention, 2017, 24, 167-170.	2.2	19

#	Article	IF	CITATIONS
55	Macrolides Blunt Aldosterone Biosynthesis. Hypertension, 2017, 70, 1238-1242.	2.7	28
56	Review of Markers of Zona Glomerulosa and Aldosterone-Producing Adenoma Cells. Hypertension, 2017, 70, 867-874.	2.7	12
57	[BP.08.05] SUBTYPING OF PRIMARY ALDOSTERONISM BY AVS. Journal of Hypertension, 2017, 35, e268.	0.5	0
58	Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression. Scientific Reports, 2017, 7, 13876.	3.3	4
59	Endothelin-1-induced endothelial mesenchimal transition via endothelin type B receptor stimulation. Journal of Hypertension, 2017, 35, 1329-1330.	0.5	2
60	Endothelinâ€1 Drives Epithelialâ€Mesenchymal Transition in Hypertensive Nephroangiosclerosis. Journal of the American Heart Association, 2016, 5, .	3.7	34
61	Estrogen Signaling in the Adrenal Cortex. Hypertension, 2016, 68, 840-848.	2.7	27
62	Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. International Journal of Cardiology, 2016, 206, 71-76.	1.7	36
63	Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1441-1450.	2.3	61
64	Assessment of the Quantitative Value Usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 19-23.	2.2	3
65	Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism. Journal of Hypertension, 2015, 33, 1014-1022.	0.5	9
66	Oral Burning With Dysphagia and Weight Loss. Medicine (United States), 2015, 94, e1163.	1.0	7
67	Heterogeneous machine learning system for improving the diagnosis of primary aldosteronism. Pattern Recognition Letters, 2015, 65, 124-130.	4.2	6
68	Systolic and diastolic short-term blood pressure variability and its determinants in patients with controlled and uncontrolled hypertension: A retrospective cohort study. Blood Pressure, 2015, 24, 124-129.	1.5	15
69	Adrenal Histopathology in Primary Aldosteronism. Hypertension, 2015, 66, 724-730.	2.7	44
70	Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease. Journal of Cardiovascular Medicine, 2015, 16, 29-36.	1.5	14
71	Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. Nephrology Dialysis Transplantation, 2015, 30, 541-553.	0.7	34
72	GPER-1 and Estrogen Receptor-Î ² Ligands Modulate Aldosterone Synthesis. Endocrinology, 2014, 155, 4296-4304.	2.8	49

#	Article	IF	CITATIONS
73	Increased level of p63RhoCEF and RhoA/Rho kinase activity in hypertensive patients. Journal of Hypertension, 2014, 32, 331-338.	0.5	55
74	Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients. Clinical Nutrition, 2014, 33, 437-442.	5.0	29
75	Lower Expression of the TWIK-Related Acid-Sensitive K+ Channel 2 (TASK-2) Gene Is a Hallmark of Aldosterone-Producing Adenoma Causing Human Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E674-E682.	3.6	48
76	KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. Journal of Hypertension, 2014, 32, 1514-1522.	0.5	42
77	Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. International Journal of Cardiology, 2013, 168, 484-489.	1.7	20
78	Elevation of Angiotensin-II Type-1-Receptor Autoantibodies Titer in Primary Aldosteronism as a Result of Aldosterone-Producing Adenoma. Hypertension, 2013, 61, 526-533.	2.7	55
79	Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design. Journal of Human Hypertension, 2013, 27, 158-163.	2.2	26
80	Changes in aldosterone and obesity-related cardiometabolic risk factors with a 1-year weight loss intervention in normotensive overweight and obese young adults. Hypertension Research, 2013, 36, 856-858.	2.7	8
81	A stress reaction affects assessment of selectivity of adrenal venous sampling and of lateralization of aldosterone excess in primary aldosteronism. European Journal of Endocrinology, 2012, 166, 869-875.	3.7	56
82	Somatic Mutations in the <i>KCNJ5</i> Gene Raise the Lateralization Index: Implications for the Diagnosis of Primary Aldosteronism by Adrenal Vein Sampling. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2307-E2313.	3.6	30
83	Hyperparathyroidism Can Be Useful in the Identification of Primary Aldosteronism Due To Aldosterone-Producing Adenoma. Hypertension, 2012, 60, 431-436.	2.7	61
84	Mild hyperparathyroidism. Journal of Hypertension, 2012, 30, 390-395.	0.5	71
85	The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design. Journal of Human Hypertension, 2012, 26, 507-516.	2.2	23
86	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	3.6	310
87	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
88	Lipoprotein-Associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients. PLoS ONE, 2012, 7, e48171.	2.5	22
89	Primary Aldosteronism: Rare or Common Condition in Hypertensive Patients and Normotensive Individuals?. , 2012, , 33-43.		0
90	The assays for renin determination: methodological remarks. Journal of Hypertension, 2011, 29, 1463-1464.	0.5	0

#	Article	IF	CITATIONS
91	Drug-related hypertension and resistance to antihypertensive treatment. Journal of Hypertension, 2011, 29, 2295-2309.	0.5	55
92	The rate of ATP export in the extramitochondrial phase via the adenine nucleotide translocator changes in aging in mitochondria isolated from heart left ventricle of either normotensive or spontaneously hypertensive rats. Mechanisms of Ageing and Development, 2011, 132, 488-495.	4.6	10
93	Chromogranin A Measurement for Assessing the Selectivity of Adrenal Venous Sampling in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E825-E829.	3.6	17
94	Exon 11 deletion in the myocyte enhancer factor (MEF)2A and early onset coronary artery disease gene in a Sicilian family. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 557-560.	2.8	8
95	A diagnostic algorithm—the holy grail of primary aldosteronism. Nature Reviews Endocrinology, 2011, 7, 697-699.	9.6	32
96	Subtyping of primary aldosteronism by adrenal vein sampling: effect of acute D2 receptor dopaminergic blockade on adrenal vein cortisol and chromogranin A levels. European Journal of Endocrinology, 2011, 165, 85-90.	3.7	7
97	Secondary Hypertension: The Ways of Management. Current Vascular Pharmacology, 2010, 8, 753-768.	1.7	11
98	The aldosterone–renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. Journal of Hypertension, 2010, 28, 1892-1899.	0.5	60
99	Response to Is the Aldosterone:Renin Ratio Truly Reproducible?. Hypertension, 2010, 55, .	2.7	0
100	Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89.	2.7	70
101	Isolation of Human Adrenocortical Aldosterone-Producing Cells by a Novel Immunomagnetic Beads Method. Endocrinology, 2010, 151, 1375-1380.	2.8	23
102	Impact of Accessory Hepatic Veins on Adrenal Vein Sampling for Identification of Surgically Curable Primary Aldosteronism. Hypertension, 2009, 54, 885-889.	2.7	78
103	Response to Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling. Hypertension, 2009, 54, .	2.7	Ο
104	Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling for Identifying Surgically Curable Subtypes of Primary Aldosteronism. Hypertension, 2009, 53, 761-766.	2.7	150
105	Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulmonary Medicine, 2008, 8, 20.	2.0	37
106	Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2008, 300, 2852.	7.4	2
107	Vascular Remodeling and Duration of Hypertension Predict Outcome of Adrenalectomy in Primary Aldosteronism Patients. Hypertension, 2008, 51, 1366-1371.	2.7	197
108	Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis. Journal of Hypertension, 2008, 26, 2022-2029.	0.5	39

#	Article	IF	CITATIONS
109	Heterogeneity of Aldosterone-Producing Adenomas Revealed by a Whole Transcriptome Analysis. Hypertension, 2007, 50, 1106-1113.	2.7	65
110	Clinical Use of Laboratory Tests for the Identification of Secondary Forms of Arterial Hypertension. Critical Reviews in Clinical Laboratory Sciences, 2007, 44, 1-85.	6.1	49
111	Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1645-51.	2.3	5
112	Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. Journal of Hypertension, 2006, 24, 851-859.	0.5	22
113	The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. Journal of Hypertension, 2006, 24, 1419-1427.	0.5	25
114	Mitochondria from the left heart ventricles of both normotensive and spontaneously hypertensive rats oxidize externally added NADH mostly via a novel malate/oxaloacetate shuttle as reconstructed in vitro. International Journal of Molecular Medicine, 2006, 18, 177-86.	4.0	7
115	Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine-Related Cancer, 2005, 12, 149-159.	3.1	107
116	Clinical Use and Pathogenetic Basis of Laboratory Tests for the Evaluation of Primary Arterial Hypertension. Critical Reviews in Clinical Laboratory Sciences, 2005, 42, 393-452.	6.1	5
117	Measures of Total Stress-Induced Blood Pressure Responses Are Associated With Vascular Damage. American Journal of Hypertension, 2005, 18, 1226-1232.	2.0	15
118	The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension. Vascular Disease Prevention, 2005, 2, 53-66.	0.2	3
119	Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. Journal of the American College of Cardiology, 2003, 41, 666-673.	2.8	94
120	Endothelial Nitric Oxide Synthase Gene Polymorphisms and Renal Survival. Hypertension, 2003, 41, e11-2; author reply e11-2.	2.7	1
121	Reciprocal regulation of endothelin-1 and nitric oxide: Relevance in the physiology and pathology of the cardiovascular system. International Review of Cytology, 2001, 209, 241-272.	6.2	75
122	Measurement of endothelin: clinical and research use. Annals of Clinical Biochemistry, 2000, 37, 608-626.	1.6	26
123	Extracellular Matrix Gene Expression in the Left Ventricular Tissue of Spontaneously Hypertensive Rats. Blood Pressure, 1999, 8, 57-64.	1.5	26
124	L-TYPE CALCIUM CHANNELS MODULATE THE REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AFTER ACE-INHIBITION IN GENETIC HYPERTENSION. Pharmacological Research, 1998, 38, 317-322.	7.1	2
125	Mitochondrial Energy Metabolism in the Left Ventricular Tissue of Spontaneously Hypertensive Rats: Abnormalities in both Adeninenucleotide and Phosphate Translocators and Enzyme Adenylate-Kinase and Creatine-Phosphokinase Activities. Clinical and Experimental Hypertension, 1998, 20, 345-358.	1.3	31
126	Carrier-mediated transport controls hydroxyproline catabolism in heart mitochondria from spontaneously hypertensive rat. FEBS Letters, 1996, 396, 279-284.	2.8	5

#	Article	IF	CITATIONS
127	Left ventricular hypertrophy in spontaneously hypertensive rat: Effects of ACE-inhibition on myocardiocyte ultrastructure. Pharmacological Research, 1995, 31, 375-381.	7.1	3
128	Antihypertensive and Metabolic Effects of Amlodipine in Patients with Non-Insulin-Dependent Diabetes Mellitus. Clinical Drug Investigation, 1995, 9, 16-21.	2.2	5
129	Left-Ventricular Hypertrophy in the Spontaneously Hypertensive Rat: Effect of ACE Inhibitors on Ultrastructural Morphology. Cardiology, 1994, 84, 14-24.	1.4	10
130	Non-invasive haemodynamic study in hypertensive subjects after treatment with verapamil slow release. Pharmacological Research, 1994, 30, 153-160.	7.1	1
131	The effects of nitrendipine on glucose tolerance and immunoreactive insulin levels in hypertensive patients. Current Therapeutic Research, 1994, 55, 1323-1334.	1.2	0
132	Study on antihypertensive efficacy of slow-release verapamil: Pharmacokinetic and noninvasive hemodynamic profile. Cardiovascular Drugs and Therapy, 1993, 7, 899-900.	2.6	0
133	Endothelins. , 0, , 143-167.		0